---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-122241"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2023-11-30T23:59:59+00:00"
generated_at: "2026-06-07T19:51:21.482006+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# AbbVie to acquire ImmunoGen for $31.26/share ($10.1B total) – adds ovarian cancer therapy ELAHERE

## Summary
- Transaction valued at $31.26 per share in cash, total equity value approx $10.1B.
- Premium of ~95% to ImmunoGen's closing price on Nov 29, 2023.
- Expected to close mid-2024; negatively impact 2024 EPS by ~$0.13, 2025 by ~$0.16, accretive from 2027.
- Key asset: ELAHERE, a first-in-class ADC approved for platinum-resistant ovarian cancer.

## SEC filing metadata
- accession: 0001104659-23-122241
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2023-11-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000110465923122241/0001104659-23-122241-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000110465923122241/tm2331814d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-122241
- JSON: https://secwatch.observer/filing/0001104659-23-122241.json
- Plain text: https://secwatch.observer/filing/0001104659-23-122241.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.